European Commission approves contract with BioNTech-Pfizer alliance
European Commission approved a fourth contract with pharmaceutical companies BioNTech and Pfizer, which provides for the initial purchase of 200 million doses on behalf of all EU Member States, plus an option to request up to a further 100 million doses, to be supplied once a vaccine has proven to be safe and effective against COVID-19. Member States can decide to donate the vaccine to lower and middle-income countries or to re-direct it to other European countries.
Today's contract with the BioNTech-Pfizer alliance builds upon the broad portfolio of vaccines to be produced in Europe, including the already signed a contracts with AstraZeneca, Sanofi-GSK and Janssen Pharmaceutica NV, and the concluded successful exploratory talks with CureVac and Moderna. This diversified vaccines portfolio will ensure Europe is well prepared for vaccination, once the vaccines have been proven to be safe and effective.
President of the European Commission, Ursula von der Leyen, said: "In the wake of Monday's promising announcement by BioNTech and Pfizer on the prospects for their vaccine, I'm very happy to announce today's agreement with the European company BioNTech and Pfizer to purchase 300 million doses of the vaccine. With this fourth contract we are now consolidating an extremely solid vaccine candidate portfolio, most of them in advanced trials phase. Once authorised, they will be quickly deployed and bring us closer to a sustainable solution of the pandemic."
Stella Kyriakides, Commissioner for Health and Food Safety, said: "A safe and effective vaccine is the only lasting exit strategy from the pandemic, and is at the centre of our European Vaccine Strategy. Today's agreement follows the encouraging first indications from the clinical trial results and is further evidence of our commitment to putting more Europe in the area of health. It is a very telling example of what the EU can achieve when working together, as a Union, and a case in point of what a future European Health Union will be able to deliver."
2026-08-19
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Pfizer and BioNTech achieve Health Canada authorization for their vaccine to com
-
Pfizer and BioNTech announce publication of results from landmark Phase 3 trial
-
Pfizer and BioNTech announce publication of results from landmark Phase 3 trial
-
FDA expert panel recommends EUA for Pfizer/BioNTech COVID-19 vaccine
-
Pfizer plans to ditch Perth sterile injectables manufacturing site by 2024
-
Pfizer and BioNTech propose expansion of pivotal COVID-19 vaccine trial
-
400 million doses! EU's first COVID-19 vaccine pre-purchase agreement to AZ
-
Isopropanol vs. Isopropyl Alcohol: Are They Different? (Uses & Safety)
-
Unilever Reports Stronger Margins and Accelerated Portfolio Transformation in FY2025
-
Univar Solutions Expands Partnership with American Distilling in EMEA to Strengthen Natural Specialty Ingredients Distribution Network
Recommend Reading
-
BASF Moves to Sell 4,400 Employee Homes—Union Fury Reveals the Survival Math of a Chemical Giant
-
The Most Striking Thing in BASF’s 2025 Results Isn’t Profit — It’s “Cutting Weight” and “Stopping the Bleeding” at the Same Time
-
From LANXESS’s 50% to Tire Makers’ 5%: The Rubber Industry Chain Is Experiencing a “Decreasing-Cost Transmission”
-
Unilever Invests 30 Billion Forints in New Deodorant Plant in Hungary
-
Sherwin-Williams Completes Acquisition of BASF's Decorative Paints Business in Brazil for $1.15 Billion
-
What is the Formula for Ammonia? (NH3 Structure & Properties)
-
Supply and Demand Easing Coupled with Bearish Moving Averages, Melamine Spot Prices Continue to Weaken in China
-
MTBE Market Trend Shows Strong Fluctuations in China
-
Demand Impacts Divergent Trends in Shandong Refinery Gasoline and Diesel Prices
-
Methanol Market Prices Undergo Slight Adjustment